Modality
Fusion Protein
MOA
PARPi
Target
PD-L1
Pathway
Lipid Met
NMOSD
Development Pipeline
Preclinical
~Sep 2009
→ ~Dec 2010
Phase 1
~Mar 2011
→ ~Jun 2012
Phase 2
~Sep 2012
→ ~Dec 2013
Phase 3
~Mar 2014
→ ~Jun 2015
NDA/BLA
~Sep 2015
→ ~Dec 2016
Approved
Mar 2017
→ Dec 2029
ApprovedCurrent
NCT07411001
2,581 pts·NMOSD
2017-03→2029-12·Active
NCT08806577
1,466 pts·NMOSD
2025-06→2027-07·Recruiting
NCT06864961
965 pts·NMOSD
2024-10→TBD·Not yet recruiting
5,012 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2025-10-106mo agoConference· NMOSD
2027-07-011.3y awayPh3 Readout· NMOSD
2029-12-143.7y awayPh3 Readout· NMOSD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Active
Approved
Not yet…
Approved
Recruit…
Catalysts
Conference
2025-10-10 · 6mo ago
NMOSD
Ph3 Readout
2027-07-01 · 1.3y away
NMOSD
Ph3 Readout
2029-12-14 · 3.7y away
NMOSD
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07411001 | Approved | NMOSD | Active | 2581 | EDSS |
| NCT08806577 | Approved | NMOSD | Recruiting | 1466 | UPCR |
| NCT06864961 | Approved | NMOSD | Not yet recr... | 965 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |